Assessment of Pregabalin-Induced Cardiotoxicity in Rats: Mechanistic Role of Angiotensin 1–7

Awwad, Zeinab M.; El-Ganainy, Samar O.; El-Mallah, Ahmed; Khedr, Shaimaa M; Khattab, Mahmoud M.; El-Khatib, Aiman S.

doi:10.1007/s12012-019-09553-6

Cited by 14 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown DIZE to have an antihypertensive effect, similar to that of ACE inhibitors [27,28]. In models of acute myocardial infarction and chronic heart failure, the administration of DIZE could reduce the size of the myocardial infarction and improve ventricular systolic and diastolic function, as well as inhibit myocardial fibrosis [14,20,24,[29][30][31]. The underlying protective mechanism of DIZE on the cardiovascular system is still unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diminazene aceturate mitigates cardiomyopathy by interfering with renin-angiotensin system in a septic rat model

Wang

et al. 2022

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background There were limited studies investigating treatments of septic cardiomyopathy (SCM), which is a common complication during sepsis. A septic rat model created by cecal ligation and puncture (CLP) was used to investigate the effects of diminazene aceturate (DIZE) in SCM. Methods A total of 151 Wistar rats were randomly assigned into the sham, CLP, or CLP + DIZE group. Data evaluated postoperatively at 6, 12, 24, and 48 hours included: cardiac function; plasma concentrations of tumor necrosis factor-alpha (TNF-α), interleukin-6, angiotensin-(1–7) [Ang-(1–7)], angiotensin II (AngII), troponin I, and brain natriuretic peptide; expression levels of myocardial Ang-(1–7), angiotensin-converting enzyme (ACE), ACE2, and angiotensin type 1 and Mas receptors; and histological changes. Results We found that the CLP + DIZE group had a lower mortality compared to the CLP group (38.5% versus 61.5%) within 48 h postoperatively, although without statistical significance. In contrast to the sham group, the CLP group had decreased cardiac functions, increased myocardial injuries, and higher TNF-α levels, which were ameliorated in the CLP + DIZE group. Furthermore, administration of DIZE could reverse the decreases of myocardial Ang-(1–7) and ACE2 expressions in the CLP group, which finally minimized the myocardial microstructure disruptions. Conclusions It was concluded that DIZE could mitigate the development of SCM and preserve cardiac function during sepsis possibly by interfering with the renin-angiotensin system through promoting myocardial ACE2 expression and restoring local Ang-(1–7) levels.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Protein expression levels of ACE, ACE2, AT1R, and MasR in cardiac tissue were determined using western blotting as previously described [ 24 ]. In brief, frozen cardiac tissues were thawed, ground, and homogenized in the lysis buffer that contained protease inhibitors, surfactants, as well as phosphatase inhibitors.…”

Section: Methodsmentioning

confidence: 99%

Diminazene aceturate mitigates cardiomyopathy by interfering with renin-angiotensin system in a septic rat model

Wang

et al. 2022

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

“…No patients who were prescribed pregabalin were admitted to ICU, although the small sample size renders this likely to be a chance phenomenon. The association of pregabalin with mortality may relate to downregulation of angiotensin‐converting enzyme 2, the SARS‐CoV‐2 functional receptor, associated with its use 30 . Further retrospective data with larger sample sizes would be required to examine this association further before justifying unlicensed use as a therapy for COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Predictors of Morbidity and Mortality in COVID‐19

Oddy

McCaul

Keeling

et al. 2021

The Journal of Clinical Pharma

View full text Add to dashboard Cite

De-identified individual participant data will be available including data dictionaries. Specifically, a case may be submitted for provision of individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices). Study documentation including the study protocol and statistical analysis plan may also be requested. Data will be available following publication ending 5 years after this date as per data handling measures specified in the study protocol. Access will be granted to requestors submitting a methodologically sound proposal to the corresponding author CO

show abstract

“…In Appendix A we summarize the main/most used drugs and food supplements that can worsen the prognosis of heart failure patients; thus, it is recommended to avoid them by this category of patients [ 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 ,…”

Section: Drugs and Food Supplements That Can Aggravate Hfmentioning

confidence: 99%

An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure

Buda

Prelipcean

Cozma

et al. 2022

JCM

View full text Add to dashboard Cite

Since the prevalence of heart failure (HF) increases with age, HF is now one of the most common reasons for the hospitalization of elderly people. Although the treatment strategies and overall outcomes of HF patients have improved over time, hospitalization and mortality rates remain elevated, especially in developed countries where populations are aging. Therefore, this paper is intended to be a valuable multidisciplinary source of information for both doctors (cardiologists and general physicians) and pharmacists in order to decrease the morbidity and mortality of heart failure patients. We address several aspects regarding pharmacological treatment (including new approaches in HF treatment strategies [sacubitril/valsartan combination and sodium glucose co-transporter-2 inhibitors]), as well as the particularities of patients (age-induced changes and sex differences) and treatment (pharmacokinetic and pharmacodynamic changes in drugs; cardiorenal syndrome). The article also highlights several drugs and food supplements that may worsen the prognosis of HF patients and discusses some potential drug–drug interactions, their consequences and recommendations for health care providers, as well as the risks of adverse drug reactions and treatment discontinuation, as an interdisciplinary approach to treatment is essential for HF patients.

show abstract

Assessment of Pregabalin-Induced Cardiotoxicity in Rats: Mechanistic Role of Angiotensin 1–7

Cited by 14 publications

References 40 publications

Diminazene aceturate mitigates cardiomyopathy by interfering with renin-angiotensin system in a septic rat model

Diminazene aceturate mitigates cardiomyopathy by interfering with renin-angiotensin system in a septic rat model

Pharmacological Predictors of Morbidity and Mortality in COVID‐19

An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure

Contact Info

Product

Resources

About